245 related articles for article (PubMed ID: 30193214)
1. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
[TBL] [Abstract][Full Text] [Related]
2. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
4. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
5. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
[TBL] [Abstract][Full Text] [Related]
6. Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
ElHady AK; Abdel-Halim M; Abadi AH; Engel M
J Med Chem; 2017 Jul; 60(13):5377-5391. PubMed ID: 28561591
[TBL] [Abstract][Full Text] [Related]
7. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
9. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
[TBL] [Abstract][Full Text] [Related]
10. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
[TBL] [Abstract][Full Text] [Related]
12. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
[TBL] [Abstract][Full Text] [Related]
13. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Mariano M; Hartmann RW; Engel M
Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
[TBL] [Abstract][Full Text] [Related]
14. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
15. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
16. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
17. Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase.
Brahmaiah D; Kanaka Durga Bhavani A; Aparna P; Sampath Kumar N; Solhi H; Le Guevel R; Baratte B; Ruchaud S; Bach S; Singh Jadav S; Raji Reddy C; Roisnel T; Mosset P; Levoin N; Grée R
Bioorg Med Chem; 2021 Feb; 31():115962. PubMed ID: 33422908
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.
Foucourt A; Hédou D; Dubouilh-Benard C; Girard A; Taverne T; Casagrande AS; Désiré L; Leblond B; Besson T
Molecules; 2014 Sep; 19(10):15411-39. PubMed ID: 25264830
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
AlNajjar YT; Gabr M; ElHady AK; Salah M; Wilms G; Abadi AH; Becker W; Abdel-Halim M; Engel M
Eur J Med Chem; 2022 Jan; 227():113911. PubMed ID: 34710745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
